Merck Still Plans To Win Big Cost Savings This Year From Schering-Plough Deal
This article was originally published in The Pink Sheet Daily
Executive Summary
Speaking at the Goldman Sachs Unplugged Conference, Merck CEO Clark says he brought in oilmen to help with modeling.
You may also be interested in...
FDA: Vytorin "Unlikely" To Cause Cancer, But More Data Coming
SHARP and IMPROVE-IT trials will allow the agency to "further assess" the potential risk.
Abbott's Niaspan/Zetia Head-To-Head Trial Deemed Too Small And Inconclusive
However, some physicians, such as Cleveland Clinic cardiologist Steve Nissen, argue the results support other, larger trials.
Cancer-Genomics Firm Quanticel Debuts With Close Ties To Celgene, And An Exit In Mind
Celgene will get exclusive use of Quanticel's single-cell genomic analysis to tweak its clinical pipeline, and it also has exclusive options to acquire the venture-backed start-up.